Trial Profile
A 2-Part, Phase 1 study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics effects of DS-3801 on gastrointestinal motility in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 May 2017
Price :
$35
*
At a glance
- Drugs DS-3801 (Primary)
- Indications Constipation; Gastrointestinal motility disorders
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 23 May 2017 New trial record
- 02 May 2017 Results published in the Journal of Clinical Pharmacology